Resources & Information

Aug 24 2017

FAQs: The STOP Act of 2017

Comments:   0 comments  Print Friendly Version  |   Share this item
NCMB has received numerous calls and emails from licensees seeking guidance about various provisions of the state’s new opioids law, the Strengthen Opioids Misuse Prevention or STOP Act.

Q: The STOP Act requires that, effective July 1, 2017, PAs and NPs practicing in pain clinics “consult” with their supervisors before prescribing any Schedule II or Schedule III opioid or narcotic. This provision took effect July 1, 2017. How does NCMB define a “consultation” between a physician assistant or nurse practitioner and his or her supervising physician?

A: The Board has directed staff to make a recommendation on what is considered a consultation. This will be presented for Board review at the September Board meeting. The Board’s intention is to adopt a rule that formally defines what type of interaction between supervisee and supervisor is required to constitute a consultation. An important consideration is whether a meaningful consultation about the patient and the recommended treatment occurs and is documented in the patient record. The Board might ultimately leave it to the discretion of PAs, NPs and their supervising physicians to determine how consultations occur (e.g. in person, via telephone or other electronic means).

Q: How is “pain clinic” defined in the STOP Act so PAs or NPs know whether they practice in one?

A: The STOP Act defines a pain clinic as “a facility that primarily engages in the treatment of pain by prescribing narcotic medications or advertises in any medium for any type of pain management services.” This definition would not normally include recognized hospice or palliative care practices which may, as a part of their usual practice, provide palliative care for pain.

Q: Effective Jan. 1, 2018, the STOP Act establishes limits on initial prescriptions for acute pain and post-surgical pain to a five day supply and a seven day supply, respectively. Is it permissible for the prescriber to authorize additional pain medication if the patient’s pain persists after the initial prescription is exhausted?

A: Yes, a prescriber may authorize additional pain medications if he or she determines more medication is clinically indicated after the initial supply has been exhausted.

Q: Does the STOP Act place any limits on how much pain medication may be initially prescribed to a patient for the treatment of chronic pain?


A: No. The STOP Act limits only initial prescriptions for acute pain and post-surgical pain. There are no limits on the amount of medication that can be prescribed to treat chronic pain in a new or established patient, although any treatment recommended should be consistent with current accepted standards of care. The prescriber would be obligated to comply with the STOP Act provision that calls for a mandatory review of the patient’s 12-month prescription history with NC CSRS before authorizing any prescription for chronic pain. Periodic CSRS reviews should be conducted every three months after the initial prescription for a Schedule II or Schedule III opioid or narcotic is written, for as long as the patient continues on the medication.

Q: How should the prescriber determine three month intervals for the purpose of periodically reviewing the 12-month NC CSRS prescription history of a patient who is continuing on Schedule II or ScheduleIII opioids or narcotics? (Mandatory use of NC CSRS will not be in effect until system upgrades are completed – date TBD)

A: NC DHHS will determine this through the NC Controlled Substances Reporting System (NC CSRS), as the STOP Act identifies NC DHHS as the agency that will audit prescribers for compliance with this provision. The most obvious option is to review the 12-month prescription history three months after the
initial prescription is written (review of the 12-month history prior to the initial prescription is also required). However the prescriber chooses to calculate the three month period, it seems important that the required review be performed before issuing another prescription for the targeted controlled substance. It might also be beneficial to be consistent and use the same method each time.

Q: How are prescribers going to manage the additional work involved with conducting NC CSRS queries and reviewing results in order to comply with the STOP Act provisions related to mandatory use of the prescription monitoring system?

A: There is no question that complying with mandatory NC CSRS use provisions will create additional work for prescribers and their staff. However, here are some points to keep in mind:
• Provisions related to mandatory registration for and use of NC CSRS do not have a firm effective date, so prescribers will have time to plan and prepare. The provisions will not go into effect until NC DHHS makes technical upgrades to NC CSRS in order to make the system more user-friendly, improve reporting capabilities, provide interstate connectivity with other Prescription Drug Monitoring Systems, and connect to the statewide health information exchange. Mandatory CSRS registration and use provisions become effective once the State Chief Information Officer confirms the required upgrades to NC CSRS are fully operational within the Department of Information Technology and the system is connected to the statewide health information exchange.
• The STOP Act also includes provisions to streamline the process of registering delegates (nurses, medical office staff) with NC CSRS. Delegates can conduct NC CSRS queries for the prescriber, who can then review the information before the patient visit. This allows the prescribers to share the workload with other members of the health care team.

Q: Are Ritalin and other medications used to treat Attention Deficit Hyperactivity Disorder (ADHD) considered “targeted controlled substances” and, thus included in the electronic prescribing and mandatory CSRS use provisions of the STOP Act?

A: No. Targeted controlled substances are Schedule II and III opioids and narcotics per the North Carolina Controlled Substances Act, specifically those listed in N.C. Gen. Stat. § 90-90(1), (2) or 90-91(d). Ritalin and other stimulants are listed in N.C. Gen. Stat. § 90-90 (3) and, thus, are not considered targeted controlled substances under the STOP Act.

At a Glance: STOP Act effective dates
July 1, 2017: PA/NP consultation with supervising physicians prior to prescribing; Hospice providers to notify families of safe disposal options for unused drugs; Streamlined process for registering delegate NC CSRS accounts; Community distribution of naloxone by organizations with standing orders
Sept. 1, 2017: Pharmacies required to report prescriptions to NC CSRS by close of business the day after a medication is delivered
Jan. 1, 2018: Limits on initial prescriptions for acute pain (no more than a five day supply) and post-operative pain (no more than a seven day supply)
Jan. 1, 2020: Electronic prescriptions required for all targeted controlled substances
Date not yet determined: Mandatory use of NC CSRS prior to prescribing Schedule II or Schedule III opioids or narcotics; Subsequent reviews required every three months thereafter

Suggest additional FAQs
Question not on our list? Suggest additional FAQs by emailing forum@ncmedboard.org

 No Comments on this article

 Post a comment on this article
Please do not include links to external websites in your comment. Please limit comments to no more than 300 words. The NCMB reserves the right to edit comments to meet the length limit. Abusive or profane remarks and personal attacks will not be published. The editor will make every effort to review and post comments in a timely fashion.